The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids

January 21, 2014 – STEMCELL Technologies Inc.

Agreement supports further development of organoids as next-generation drug screening platform

Utrecht, January 17, 2014 – The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

“We are pleased that STEMCELL will be our partner in making specialty media for growth of organoids available to the scientific community”, says Prof. Hans Clevers, one of the founding directors of the HUB. “The broad availability of off-the-shelf cell culture media from a world leader in the development of specialized cell culture media and cell separation products represents an essential step in the further implementation of this exciting technology”.

“We are delighted to bring these important culture media products quickly and reliably to researchers for the growth of tissue-specific organoids, and to be the exclusive commercial supplier,” says Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “The first product under this license will be released soon for culture of murine organoids, with products for human tissue to follow”.

About the HUB

The HUB is a not-for-profit organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. The HUB exploits the pioneering work of Prof. Hans Clevers who discovered methods to grow stem cell-derived human ‘mini-organs’ (organoids) from tissues of patients with various diseases. The organoids, that are part of the Living Biobank, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. The HUB offers licenses to its patented Organoid Technology for drug-screening and access to organoids in the Living Biobank for preclinical drug discovery and validation. In addition, the HUB provides drug screening services to third parties.

About STEMCELL Technologies

STEMCELL Technologies Inc is a privately-owned biotechnology company that develops specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science and a passion for quality, STEMCELL delivers over 1500 products to more than 70 countries worldwide.

Contact Information
The HUB – Dr. Robert Vries
Uppsalalaan 8
3584 CT, Utrecht – The Netherlands
visit us at:

STEMCELL – Luba Metlitskaia, MSc.
Director, Licensing and Business Development
Suite 400-1618 Station Street
Vancouver, British Columbia – Canada
visit us at: